BBA
CLDX icon

Baker Bros. Advisors’s Celldex Therapeutics CLDX Stock Holding History

Baker Bros. Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44M Buy
1,182,611
+517,241
+78% +$16.7M 0.22% 40
2026
Q1 		$21.1M Hold
665,370
– – 0.12% 51
2025
Q4 		$18.1M Hold
665,370
– – 0.11% 56
2025
Q3 		$17.2M Hold
665,370
– – 0.12% 47
2025
Q2 		$13.5M Buy
665,370
+417,726
+169% +$8.13M 0.13% 48
2025
Q1 		$4.49M Hold
247,644
– – 0.05% 61
2024
Q4 		$6.26M Hold
247,644
– – 0.07% 64
2024
Q3 		$8.42M Hold
247,644
– – 0.09% 57
2024
Q2 		$9.17M Hold
247,644
– – 0.12% 51
2024
Q1 		$10.4M Hold
247,644
– – 0.13% 48
2023
Q4 		$9.82M Buy
+247,644
New +$7.28M 0.11% 48

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baker Bros. Advisors's CLDX Position: Q2 2026 in Review

Baker Bros. Advisors increased its Celldex Therapeutics (CLDX) stake by 78% in Q2 2026, buying an estimated $16.7M and bringing the position to 1,182,611 shares worth $44M. The position accounts for 0.22% of the portfolio, ranked #40.

Baker Bros. Advisors first reported a position in CLDX in Q4 2023 and has held it in 11 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Baker Bros. Advisors held 1,182,611 shares of Celldex Therapeutics worth $44M as of Q2 2026.
  • Baker Bros. Advisors bought 517,241 Celldex Therapeutics shares in Q2 2026, an estimated $16.7M.
  • Celldex Therapeutics made up 0.22% of Baker Bros. Advisors's portfolio in Q2 2026, its #40 holding.
  • Baker Bros. Advisors first reported a position in Celldex Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.